Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma

Urology

Volumn 68, Issue 3, 2006, Pages 523-527

  Kawata, Nozomu ^a   Nagane, Yusuke ^a   Igarashi, Takumi ^a   Hirakata, Hitoshi ^a   Ichinose, Taketo ^a   Hachiya, Takahiko ^a   Takimoto, Yukie ^a   Takahashi, Satoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYMPTOMATOLOGY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 33748925380     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.03.063     Document Type: Article

References (24)

1. Tsui K., Shvarts O., Smith R.B., et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 163 (2000) 426-433
2. McDougal W.S., and Garnick M.B. Clinical signs and symptoms of renal cell carcinoma. In: Vogelzang N.J., Scardino P.T., Shipley W.U., et al. (Eds). Comprehensive Textbook of Genitourinary Oncology (1995), Williams & Wilkins, Baltimore 111-115 Chapter IV, 154-159
3. Blay J.Y., Rossi J.F., Wijdenes J., et al. Role of IL-6 in the paraneoplastic inflammatory syndrome associated with renal cell carcinoma. Int J Cancer 72 (1997) 424-430
4. Kawata N., Yamaguchi K., Hirakata H., et al. Immunosuppressive acidic protein detects high nuclear grade localized renal cell carcinoma. Urology 66 (2005) 736-740
5. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58 (2001) 141-145
6. Patard J.J., Leray E., Cindolo L., et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172 (2004) 858-862
7. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
8. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
9. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2 (2002) 657-672
10. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumours. 5th ed. (1997), John Wiley, New York
11. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significant of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
12. Lang H., Lindner V., Saussine C., et al. Microscopic venous invasion: a prognostic factor in renal cell carcinoma. Eur Urol 38 (2000) 600-605
13. Kawamata H., Kameyama S., Kawai K., et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of the human gelatinase. A. Int J Cancer 63 (1995) 568-575
14. Tsunezuka Y., Kinoh H., Takino T., et al. Expression of membrane-type matrix metalloproteinases 1 (MT1-MP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56 (1996) 5678-5683
15. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissue: clinical and experimental applications. Ann NY Acad Sci 878 (1999) 212-227
16. Gohji K., Fujimoto N., Komiyama T., et al. Evaluation of serum levels of matrix metalloproteinases-2 and 3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78 (1996) 2379-2387
17. Kugler A., Hemmerlein B., Thelen P., et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160 (1998) 1914-1918
18. Lein M., Jung K., Laube C., et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 85 (2000) 801-804
19. Fukata S., Inoue K., Kamada M., et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103 (2005) 931-942
20. Wilhelm S.M., Collier I.E., Marmer B.L., et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264 (1989) 17213-17221
21. Okada Y., Gonoji Y., Naka K., et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymic properties. J Biol Chem 267 (1992) 21712-21719
22. Kim J., Yu W., Kovalski K., et al. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94 (1998) 353-362
23. Gomez D.E., Alonso D.F., Yoshiji H., et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
24. Laski M.E., and Vugrin D. Paraneoplastic syndromes in hypernephroma. Semin Nephrol 7 (1987) 123-130